User Settings
Article10.1161/circ.124.suppl_21.a9811

Abstract 9811: Medical Resource Use, Costs and Quality of Life are Similar Between Patients with Acute Decompensated Heart Failure Treated with Nesiritide Versus Placebo

Shelby D. Reed,Padma Kaul,Adrian F. Hernandez,Yanhong Li,Zubin J. Eapen,Kevin A. Schulman+8 more-2011-11-22-Circulation
0

TL;DRAbstract

Introduction: In the recent Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF), treatment with nesiritide did not reduce heart failure rehospitalization or mortality at 30 days relative to treatment with placebo. Dyspnea was marginally improved with nesiritide, but did not reach pre-specified levels for statistical significance. Our study reports on a prospective economic and quality of life evaluation that was conducted as part of the trial. Objective: Compare medical resource use, costs and quality of life outcomes between patients randomized to nesiritide versus placebo in the ASCEND-HF. Methods: Detailed resource use data, including data on length of stay and readmissions within 30 days were collected on the case report form. Quality of life was assessed using the EQ-5D, administered at baseline, 24 hours, discharge, and 30 days. Hospital billing data representing 1253 admissions for US patients were used to develop a cost predictio

Chat with Paper

AI Agents for this Paper

Introduction: In the recent Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF), treatment with nesiritide did not reduce heart failure rehospitalization or mortality at 30 days relative to treatment with placebo. Dyspnea was marginally improved with nesiritide, but did not reach pre-specified levels for statistical significance. Our study reports on a prospective economic and quality of life evaluation that was conducted as part of the trial. Objective: Compare medical resource use, costs and quality of life outcomes between patients randomized to nesiritide versus placebo in the ASCEND-HF. Methods: Detailed resource use data, including data on length of stay and readmissions within 30 days were collected on the case report form. Quality of life was assessed using the EQ-5D, administered at baseline, 24 hours, discharge, and 30 days. Hospital billing data representing 1253 admissions for US patients were used to develop a cost predictio

Keywords

NesiritideMedicineHeart failureAcute decompensated heart failurePlaceboIntensive care medicineQuality of life (healthcare)Cardiology

Chat

Click to start Chat